Status:
COMPLETED
Registry of Patients With Hematologic Disease and COVID-19 in Russia
Lead Sponsor:
National Research Center for Hematology, Russia
Collaborating Sponsors:
Foundation for Cancer Research Support (RakFond)
Enrollme.ru, LLC
Conditions:
Coronavirus Infection and Hematologic Diseases
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
Detailed Description
This is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in t...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age 18 or older
- Any previously or currently diagnosed hematologic disease
- Laboratory confirmed or suspected (based on clinical symptoms and/or CT) COVID-19
- Known outcome of COVID-19 in case of retrospective data input (protocol allows retrospective data input for patients who were prospectively followed in local centers)
- Exclusion Criteria
- • Loss of follow-up within 30 days after COVID-19 diagnosis
Exclusion
Key Trial Info
Start Date :
June 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 18 2022
Estimated Enrollment :
666 Patients enrolled
Trial Details
Trial ID
NCT04422470
Start Date
June 22 2020
End Date
January 18 2022
Last Update
January 26 2023
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Republican Clinical Hospital of Tatarstan
Kazan', Russia
2
City Hospital n.a. V.V. Veresaev
Moscow, Russia
3
Clinical Hospital n.a. S.P. Botkin
Moscow, Russia
4
N.V. Sklifosovsky Emergency Institute
Moscow, Russia